CALR
CALR (Calreticulin) is a gene. The public catalogues list it as a drug target, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Essential thrombocythaemia and Primary myelofibrosis.
Overview
Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesised in the ER. Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export.
CIViC holds 8 clinical evidence items and 0 assertions across 2 variants, naming Peginterferon Alfa-2a. Open Targets scores its association with cancer at 0.79 (direct and indirect evidence; datatypes literature 0.99, genetic association 0.82, somatic mutation 0.87, genetic literature 0.30). In OnCo, 1 product record names it (Ruxolitinib).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CALR (Calreticulin) is a gene. The public catalogues list it as a drug target, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Essential thrombocythaemia and Primary myelofibrosis.
- 1 · What it is
CALR (Calreticulin) is a gene. The public catalogues list it as a drug target, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Essential thrombocythaemia and Primary myelofibrosis.
- 2 · What goes wrong in cancer
Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle.
- 3 · How drugs use it
No product in this corpus aims at CALR yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:1455 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P27797 (protein name, function text, keywords and locations (REST API)); CIViC gene CALR (8 evidence items, 0 assertions, 2 variants; diseases: Myelofibrosis, Essential Thrombocythemia (GraphQL API, CC0)); Open Targets ENSG00000179218 (association with cancer (MONDO_0004992) 0.79; per-cancer scores at or above 0.5: myeloproliferative neoplasm 0.73, primary myelofibrosis 0.56 (GraphQL API, CC0))
Biology
Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesised in the ER. Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export. Involved in maternal gene expression regulation. May participate in oocyte maturation via the regulation of calcium homeostasis. Present in the cortical granules of non-activated oocytes, is exocytosed during the cortical reaction in response to oocyte activation and might participate in the block to polyspermy. Location: Endoplasmic reticulum lumen; Cytoplasm, cytosol; Secreted, extracellular space, extracellular matrix; Cell surface (UniProt). Locus 19p13.13 (HGNC).
- Myeloproliferative neoplasms: Open Targets association 0.73 with myeloproliferative neoplasm (MONDO_0020076)
- Essential thrombocythaemia: CIViC evidence names this disease
- Primary myelofibrosis: Open Targets association 0.56 with primary myelofibrosis (MONDO_0009692)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 8 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Myelofibrosis.
Latest papers
topQuery for this target: (TITLE:"CALR" OR ABSTRACT:"CALR" OR TITLE:"calreticulin" OR ABSTRACT:"calreticulin" OR TITLE:"Calreticulin" OR ABSTRACT:"Calreticulin" OR TITLE:"cC1qR" OR ABSTRACT:"cC1qR" OR TITLE:"FLJ26680" OR ABSTRACT:"FLJ26680" OR TITLE:"CALR1" OR ABSTRACT:"CALR1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CALR, not a curated reading list.
Similar pages
not linked directly; found by shared links- TermPost-PV myelofibrosis (spent phase)
Shares Essential thrombocythaemia (ET), Ruxolitinib, Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TargetPDE3A
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
- TargetPDE3B
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
- TermJAK2 V617F
Shares Essential thrombocythaemia (ET), Ruxolitinib, Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- Key paperCOMFORT-II: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Shares Ruxolitinib, Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TrialA Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Shares Ruxolitinib, Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TrialCOMFORT-I
Shares Ruxolitinib, Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TrialCOMFORT-II
Shares Ruxolitinib, Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis).